ÂÜÀòÂÒÂ×

Dr. Mark Kahn is the Chief Medical Officer and Co-Founder at Osciflex. Mark was formerly a Fellow at the University City Science Center, where they evaluated technology for commercialization and conducted market analysis. Prior to that, Dr. Kahn was a Postdoctoral Fellow in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania. There, they investigated endothelial gene expression changes in response to hemodynamic changes and developed novel mouse models of thrombosis. Mark also developed assays to collect and analyze lymphatic fluid from the mouse thoracic duct, and used intravital imaging techniques to investigate the role of platelets in regulating lymphatic flow. Before their time at the University of Pennsylvania, Dr. Kahn was a Research Fellow at Los Alamos National Laboratory.

Mark Kahn received a Bachelor's degree in Biology/Biological Sciences, General from Virginia Tech. Mark then went on to receive a Master's degree in Cell/Cellular and Molecular Biology from Virginia Tech as well. Finally, Mark Kahn received their Doctor of Philosophy - PhD in Biochemistry, Biophysics and Molecular Biology from the University of Pennsylvania.

Mark Kahn reports to John Welsh, CEO & Co-Founder. They are on a team with Mercedes Wesner - Product Development Lead, Alex Santos - Product Development Lead.